Clinical

Though COVID-19 case numbers are slowly coming down in some regions of the United States, the Omicron variant still driving hospitalization rates higher from coast to coast. So, it’s a bit daunting to learn that a “new” subvariant of Omicron, dubbed BA.2, has been reported in 40 countries—including the U.S.—as of January 24. According to the World Health Organization, BA.2 comprises four lineages: B.1.1.529, BA.1, BA.2 and BA.3. While mainstream media outlets have quoted various scientists …

We found out shortly after its discovery that the Omicron variant of COVID-19 is more transmissible but (for most patients) less severe than others. As research continues, however, even more disparities are becoming known—and a couple of the latest could affect how you approach to both testing and office hygiene. An article just published online by Reuters quotes multiple studies in the U.S. and abroad revealing the optimal method of testing for Omicron and how …

The Omicron variant of COVID-19 has been shown to produce less severe illness than previous varieties of the virus—for the most part. Much of the data assembled, to date, reflect lower risk for hospitalization and death in vaccinated patients. The unvaccinated or not fully vaccinated don’t necessarily run the same low risk. Perhaps more importantly, the World Health Organization just shared circumstances in which patients may be at high risk for severe disease even with …

It’s been well established that vaccination is the best option for reducing risk for infection with SARS-CoV-2, but also in avoiding severe disease and poor outcomes in breakthrough cases. New data published in Morbidity and Mortality Weekly Report shed some light on exactly which patients are still at increased risk for hospitalization or death from the virus even though they’re fully vaccinated (defined for purposes of the research as receiving a full complement of one …

A few months ago, we shared the findings of a study published in the Journal of the American Medical Association indicating that a 5-day course of remdesivir improved outcomes for hospitalized patients with “moderate-to-severe” COVID-19. Further study by another group of researchers now shows that a 3-day course reduced risk for hospitalization or death in patients with COVID-19 and certain comorbidities but who had not yet been hospitalized with the virus. The latest study, published …

The sharp rise in COVID-19 cases attributed to the Omicron variant so close after the winter holidays is a nonscientific (but probably accurate) indicator that people spent a lot of time in tight quarters, unmasked, with others whose immunization or exposure status was unknown to them. The more ominous prospect, given that many individuals got rapid tests (or insisted that visitors do so) before gathering, is that rapid antigen tests may not be much help …

Due to supply chain concerns and the ongoing rapid rise in COVID-19 cases in the United States, the U.S. Department of Health and Human Services says it is moving to a weekly allocation cycle for related therapeutics for 3 weeks, starting January 3. HHS says it has stopped allocating bam/ete or Regen-COV to jurisdictions with 80% or more prevalence of the Omicron variant, given that data from the Centers for Disease Control and Prevention indicate …

This is the second flu season in a row that the healthcare community has held its breath waiting to see if the United States would be hit with dual widespread outbreaks of COVID-19 and influenza (aka, a twindemic). And so far, in spite of another COVID surge fueled by the Omicron variant, so good on that front. However, public health officials here and in other countries are reporting an increase in flurona—or, simultaneous diagnoses of …

New data from the UK Health Security Agency indicate that booster shot protection against symptomatic COVID-19 caused by the Omicron variant fades within 10 weeks or so. There’s no indication as to whether that means boosters are any more or less successful at preventing severe disease in those who do become infected with the Omicron variant of the virus. The research shows that providing two doses of the AstraZeneca vaccine (available in the UK but …

The Food and Drug Administration officially blessed the practice of providing COVID-19 booster shots to 12- to 15-year-old children, as well as for immunocompromised children between 5 and 11 years of age. In the same announcement, the FDA shortened the recommended interval between initial vaccination and boosters for some patients. Based on “new evidence,” the agency suggests that patients who received two doses of the Pfizer vaccine get a booster shot 5 months after completing …